Important Disclosures J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. To maximize the impact of these genetic insights, the ability to alter the human genome at the foundational level of genetic information - a single base - is crucial. – ALL RIGHTS RESERVED, Insider Ratings Definition - IPO Calendar - Privacy Policy - Contact Us, Download Best WordPress Themes Free Download. To maximize the impact of these genetic insights, the ability to alter the human genome at the foundational level of genetic information – a single base – is crucial. Beam Therapeutics Announces Proposed Public Offering of Common Stock. (BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. Renaissance Capital Investments, Inc. is a FINRA-registered broker-dealer, and member of SIPC. Google, UnderArmour and Facebook were holdings in our IPO investment strategies These point mutations represent approximately 58% of all the known genetic errors associated with disease. (-0.6%). Other natural genetic variations of a single base among human populations, revealed by population-level genomic studies, are known to protect against disease. We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES), 26 Landsdowne Street, 2nd Floor, Cambridge, MA 02139, US, COPYRIGHT © 2018 IPO INSIDER LLC. We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager. $28.49 These point mutations represent approximately 58% of all the known genetic errors associated with disease. In the last decade, the field of genetic medicine has reached an inflection point, with groundbreaking advances in gene therapy, cell therapy, oligonucleotides, and, more recently, gene editing. -0.18 IPO Intelligence research provides institutional investors with top down tracking While these technologies represent dramatic advancements for genetic medicines, the ability to edit genes at the single base level has been elusive. The company’s stock price was up nearly 40% as of 11:45 a.m. Investors Arch Venture partners and F-Prime Capital Partners held 21% and 18% respective stakes in Beam leading up to the IPO. Get your FREE TRIAL now. The company issued 6,300,000 shares at $15.00-$17.00 per share. Renaissance Capital is the global leader in providing pre-IPO institutional Explore our IPO Center to track upcoming deals, analyze performance and read IPO news and expert commentary. Beam hopes to ask the FDA for permission to launch its first clinical trial in 2021. - Renaissance Capital Latest Trade: Other natural genetic variations of a single base among human populations, revealed by population-level genomic studies, are known to protect against disease. Preclinical biotech developing therapies based on single-base gene editing. when they were newly public. of the global IPO market and bottom up research and valuation analysis on every IPO. Don't risk buying another IPO without IPO Pro. research and management of IPO-focused investment products. Beam Therapeutics To Present First Data Highlighting Base Editing Program For Alpha-1 Antitrypsin Deficiency At 23rd ASGCT Annual Meeting By GlobeNewswire Apr 28, 2020 4:35 PM EDT CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a … (BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The most common class of genetic mutations are errors of a single base, known as point mutations. The most common class of genetic mutations are errors of a single base, known as point mutations. All rights reserved. Renaissance Capital LLC is an SEC-registered investment adviser. © 2020 Renaissance Capital LLC. Everything you need to know about the Beam Therapeutics IPO including Offer Price, Filed Date, IPO Date, Offer Shares, Dealsize and Underwriters. Thinking of investing in new companies before they become household names? The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. We are a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. Assuming the IPO takes place, Beam Therapeutics and base editing offer investors a technological upgrade over the first-generation gene editing platforms leaning on CRISPR-CasX tools.